Compare AstraZeneca plc (AZN) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Exxon Mobil Corporation — how do they compare? AstraZeneca plc trades at $168.7 (market cap $253.13B), while Exxon Mobil Corporation trades at $143.81 (market cap $601.39B). The key difference: Exxon Mobil Corporation is far larger — about 2.4× AstraZeneca plc's market cap, and Exxon Mobil Corporation pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| AZN | XOM | |
|---|---|---|
Market Cap | $253.13B | $601.39B |
Sector | Health | Energy |
52-Week High | $209.48 | $171.52 |
52-Week Low | $137.44 | $105.83 |
Enterprise Value | $279.37B | $640.62B |
Dividend Yield | 1.92% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
ExxonMobil (XOM) trades at $144.51, up 4.1% today, with a bullish technical outlook and strong earnings beats in recent quarters. The stock shows robust profitability with a net income margin of 7.76% and a solid balance sheet, though revenue and net income have declined from 2022 peaks. Recent news highlights Exxon's Permian Basin advantages and potential oil price spikes, supporting positive sentiment.
XOM offers value with a consensus price target of $169.30, implying 17% upside, but faces risks from volatile oil prices and declining profit margins. Institutional buy ratings at 40.74% reflect cautious optimism, while technical indicators suggest near-term resistance at $146. Investors should weigh the strong cash flow and dividend against energy market uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
